These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

729 related items for PubMed ID: 25609338

  • 1. Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms.
    Kruse K, Gerwin E, Eichel A, Shah-Hosseini K, Mösges R.
    J Allergy Clin Immunol Pract; 2015; 3(3):381-6. PubMed ID: 25609338
    [Abstract] [Full Text] [Related]

  • 2. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
    Didier A, Worm M, Horak F, Sussman G, de Beaumont O, Le Gall M, Melac M, Malling HJ.
    J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
    [Abstract] [Full Text] [Related]

  • 3. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S.
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [Abstract] [Full Text] [Related]

  • 4. Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen-induced allergic rhinoconjunctivitis in an environmental exposure unit.
    Ellis AK, Tenn MW, Steacy LM, Adams DE, Day AG, Walker TJ, Nolte H.
    Ann Allergy Asthma Immunol; 2018 May; 120(5):495-503.e2. PubMed ID: 29432967
    [Abstract] [Full Text] [Related]

  • 5. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis.
    Didier A, Malling HJ, Worm M, Horak F, Sussman G, Melac M, Soulié S, Zeldin RK.
    Clin Exp Allergy; 2013 May; 43(5):568-77. PubMed ID: 23600548
    [Abstract] [Full Text] [Related]

  • 6. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
    Valovirta E, Jacobsen L, Ljørring C, Koivikko A, Savolainen J.
    Allergy; 2006 Oct; 61(10):1177-83. PubMed ID: 16942565
    [Abstract] [Full Text] [Related]

  • 7. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K, Gessner C, Kroker A, Schwab JA, Pohl W, Villesen H, Wüstenberg E, Emminger W.
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children.
    Stelmach I, Kaluzińska-Parzyszek I, Jerzynska J, Stelmach P, Stelmach W, Majak P.
    Allergy; 2012 Mar; 67(3):312-20. PubMed ID: 22142341
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
    Bufe A, Ziegler-Kirbach E, Stoeckmann E, Heidemann P, Gehlhar K, Holland-Letz T, Braun W.
    Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830
    [Abstract] [Full Text] [Related]

  • 11. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O, Wolf H, Klimek L, Schnitker J, Wüstenberg E.
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy.
    Calderon MA, Birk AO, Andersen JS, Durham SR.
    Allergy; 2007 Aug; 62(8):958-61. PubMed ID: 17620076
    [Abstract] [Full Text] [Related]

  • 16. Cc-chemokine eotaxin as a marker of efficacy of specific immunotherapy in patients with intermittent IgE-mediated allergic rhinoconjunctivitis.
    Jahnz-Rózyk K, Targowski T, Głodzinska-Wyszogrodzka E, Płusa T.
    Allergy; 2003 Jul; 58(7):595-601. PubMed ID: 12823117
    [Abstract] [Full Text] [Related]

  • 17. Immunotherapy With the SQ Tree SLIT-tablet in Adults and Adolescents With Allergic Rhinoconjunctivitis.
    Mäkelä MJ, Gyllfors P, Valovirta E, Steffensen MA, Grønager PM, Savolainen J, Winther L.
    Clin Ther; 2018 Apr; 40(4):574-586.e4. PubMed ID: 29551533
    [Abstract] [Full Text] [Related]

  • 18. Treatment with grass allergen peptides improves symptoms of grass pollen-induced allergic rhinoconjunctivitis.
    Ellis AK, Frankish CW, O'Hehir RE, Armstrong K, Steacy L, Larché M, Hafner RP.
    J Allergy Clin Immunol; 2017 Aug; 140(2):486-496. PubMed ID: 28236469
    [Abstract] [Full Text] [Related]

  • 19. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
    Roberts G, Hurley C, Turcanu V, Lack G.
    J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125
    [Abstract] [Full Text] [Related]

  • 20. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
    Dahl R, Stender A, Rak S.
    Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.